EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia

John T Butler iD, William M Yashar, Ronan Swords

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27586 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2025. Verfasst von John T Butler und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine and Applied Science, Moores Cancer Center, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Bone Marrow. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Division of Cancer Prevention, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a genetically heterogeneous disease with high rates of relapse after initial treatment. Identifying measurable residual disease (MRD) following initial therapy is essential to assess response, predict patient outcomes, and identify those in need of additional intervention. Currently, MRD analysis relies on invasive, serial bone marrow (BM) biopsies, which complicate sample availability and processing time and negatively impact patient experience. Additionally, finding a positive result can generate more questions than answers, causing anxiety for both the patient and the provider. Peripheral blood (PB) evaluation has shown promise in detecting MRD and is now recommended by the European Leukemia Net for AML for certain genetic abnormalities. PB‐based sampling allows for more frequent testing intervals and better temporal resolution of malignant expansion while sparing patients additional invasive procedures. In this review, we will discuss the current state of PB testing for MRD evaluation with a focus on next‐generation sequencing methodologies that are capable of MRD detection across AML subtypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteBone MarrowHumansHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

acute myelogenous leukemiabiomarkercfDNActDNAmeasurable residual diseaseperipheral blood

Autor:innen und Institutionen

  • Radiation Medicine and Applied Science, Moores Cancer Center, University of California San Diego, La Jolla, California, USA.
  • Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Division of Oncologic Sciences, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: John T Butler

Förderung

  • NCI NIH HHS
  • Division of Cancer Prevention, National Cancer Institute

Zitieren

APA

Butler, J. T., Yashar, W. M., & Swords, R. (2025). Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27586

Vancouver

Butler JT, Yashar WM, Swords R. Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia. American Journal of Hematology. 2025. doi:10.1002/ajh.27586

BibTeX
@article{Butler2025,
  author = {Butler, John T and Yashar, William M and Swords, Ronan},
  title = {Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27586}
}
Kostenlos starten →